NCT02564094View on ClinicalTrials.gov

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Anemia
Interventions
DRUG

Epoetin beta

Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.

Trial Locations (9)

1527

Sofia

1756

Sofia

1757

Sofia

1784

Sofia

4000

Plovdiv

4004

Plovdiv

8000

Stara Zagora

9002

Varna

9010

Varna

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02564094 - A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies | Biotech Hunter | Biotech Hunter